JPWO2019213589A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019213589A5
JPWO2019213589A5 JP2020561635A JP2020561635A JPWO2019213589A5 JP WO2019213589 A5 JPWO2019213589 A5 JP WO2019213589A5 JP 2020561635 A JP2020561635 A JP 2020561635A JP 2020561635 A JP2020561635 A JP 2020561635A JP WO2019213589 A5 JPWO2019213589 A5 JP WO2019213589A5
Authority
JP
Japan
Prior art keywords
lymphoma
composition
cell lymphoma
effective amount
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523114A5 (https=
JP2021523114A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030690 external-priority patent/WO2019213589A1/en
Publication of JP2021523114A publication Critical patent/JP2021523114A/ja
Publication of JPWO2019213589A5 publication Critical patent/JPWO2019213589A5/ja
Publication of JP2021523114A5 publication Critical patent/JP2021523114A5/ja
Priority to JP2024001279A priority Critical patent/JP2024024093A/ja
Pending legal-status Critical Current

Links

JP2020561635A 2018-05-04 2019-05-03 リンパ腫の治療方法 Pending JP2021523114A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001279A JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862667249P 2018-05-04 2018-05-04
US62/667,249 2018-05-04
US201862678934P 2018-05-31 2018-05-31
US62/678,934 2018-05-31
US201862736047P 2018-09-25 2018-09-25
US62/736,047 2018-09-25
PCT/US2019/030690 WO2019213589A1 (en) 2018-05-04 2019-05-03 Methods for treating lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001279A Division JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Publications (3)

Publication Number Publication Date
JP2021523114A JP2021523114A (ja) 2021-09-02
JPWO2019213589A5 true JPWO2019213589A5 (https=) 2022-05-18
JP2021523114A5 JP2021523114A5 (https=) 2022-05-18

Family

ID=66554509

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561635A Pending JP2021523114A (ja) 2018-05-04 2019-05-03 リンパ腫の治療方法
JP2024001279A Pending JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001279A Pending JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Country Status (11)

Country Link
US (3) US11266645B2 (https=)
EP (1) EP3787628A1 (https=)
JP (2) JP2021523114A (https=)
KR (1) KR20210003789A (https=)
CN (1) CN112074271B (https=)
AU (1) AU2019262644A1 (https=)
BR (1) BR112020022430A2 (https=)
CA (1) CA3098012A1 (https=)
MX (1) MX2020011817A (https=)
TW (1) TW202014190A (https=)
WO (1) WO2019213589A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2023091785A1 (en) * 2021-11-22 2023-05-25 Secura Bio, Inc. Methods for treating peripheral t-cell lymphoma
CN114306606B (zh) * 2021-11-29 2023-05-26 江苏省人民医院（南京医科大学第一附属医院） cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
WO2024115935A1 (en) * 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
CN117427166B (zh) * 2023-09-25 2024-09-10 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Csf1r抑制剂用于制备nk/t细胞淋巴瘤治疗药物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP1845778A2 (en) 2005-01-10 2007-10-24 University Of Virginia Patent Foundation Synthesis of inhibitors of p90rsk
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2016196385A1 (en) * 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
AU2016363005A1 (en) * 2015-12-04 2018-07-05 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers

Similar Documents

Publication Publication Date Title
JP2021523114A5 (https=)
JP7777624B2 (ja) 糖尿病性末梢神経障害のための医薬
AU2025213576A1 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
JP6815728B2 (ja) 新規の使用
JP2010043101A (ja) 組合せ
CN110402140A (zh) 加波沙朵在治疗耳鸣中的用途
JPWO2019213589A5 (https=)
TW202207942A (zh) 包含ｃｒａｆ抑制劑的治療組合
JPS62120317A (ja) 痴呆症状改善・治療剤
JP4380800B2 (ja) マラリアの処置のための（＋）メフロキンの使用
ES2313394T3 (es) Combinacion de transcriptasa inversa anti-hiv e inhibidores de proteasa.
HUE028025T2 (en) Use of Panobinostat HDAC inhibitor to treat myeloma
EA011420B1 (ru) Профилактика вич-инфекции
JP2002515892A (ja) サイトカインが関係する疾患治療法
US20230321110A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
CA2504665C (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
CA3200986A1 (en) Raf inhibitor for treating low grade glioma
JPWO2003011296A1 (ja) アミノベンゼンスルホン酸誘導体を活性成分とする医薬品製剤
CN111343983A (zh) 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
RU2020137882A (ru) Способы лечения лимфомы
EP3130339B1 (en) A compound for use in the treatment of comorbid anxiety disorder and depression disorder
CN101282728A (zh) 有机化合物的组合
WO1995020388A1 (en) Anti-hiv drugs
Freerksen et al. Malaria therapy and prophylaxis with cotrifazid, a multiple complex combination consisting of rifampicin+ isoniazid+ sulfamethoxazole+ trimethoprim